Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
- Chuikyo Moots Possible Expansion of “Essential Drugs”; MHLW Pitches Antibacterial Eye Drops
October 30, 2017
- Kamoya Leaves Chuikyo as Industry Rep, Lauds Breakthrough for Essential Drug Rule
October 30, 2017
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
- CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
- MHLW Issues Notification Revising GPSP Ordinance in Response to Medical Information Database
October 27, 2017
- Scrap Price Maintenance Premium, or Limit Scope of Products: MOF
October 26, 2017
- Chuikyo Proposes 5% ICER Deduction for Each Ethical/Societal Criteria Met
October 26, 2017
- Chuikyo OKs “5 Million Yen,” “10 Million Yen” Thresholds for 3-Segment CEA Price Adjustment Model
October 26, 2017
- Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo
October 26, 2017
- Consumer Representative on MHLW Advisory Panel Resigns after Taking Regular Payments from Megmilk Snow Brand
October 26, 2017
- Patient Dies due to Mix-Up of Lixiana, Rifxima; PMDA, Companies Issue Warning Statement
October 26, 2017
- Cabinet Approves 5-Year Plan to Promote Anticancer Measures
October 26, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6
October 25, 2017
- Conditional Early Approval System Gets Underway: MHLW
October 23, 2017
- LDP Healthcare Big Names Handily Nab Seats in Snap Election
October 23, 2017
- MHLW to Discuss Drug Wholesalers’ License Requirements Related to Their “Operational Systems”
October 23, 2017
- MHLW to Discuss Redefinition of Drug “Seals”, Will Revise List of Examples of Seals Included in 1961 Notification
October 23, 2017
- Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
- MHLW Advisory Panel to Discuss Pediatric Dosages for Nexium on Nov. 2
October 20, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…